RxDoctor Payments Data

Tuan le

Medical · Garden Grove, CANPI 1417210204

Payments from drug & device makers

$11,749in general payments, 2019–2025

Across 200 payments — averaging $58.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$1K
  • Novo Nordisk$1K
  • GSK$730
  • Bayer$680
  • Lilly USA, LLC$613
  • plus $6K from 35 others

What the payments were for

  • Travel & lodging$40%
  • Food & beverage$11,731100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,749 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$66,402
Medicare patients
341
Services billed
785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin148$123,300
FarxigaDapagliflozin Propanediol75$71,620
JanuviaSitagliptin Phosphate70$63,984
CreonLipase/Protease/Amylase40$53,142
ProliaDenosumab27$43,940
EliquisApixaban52$42,858
TrulicityDulaglutide31$39,660
VascepaIcosapent Ethyl108$39,375
ZenpepLipase/Protease/Amylase28$37,955
VemlidyTenofovir Alafenamide17$29,784
JanumetSitagliptin Phos/Metformin Hcl19$28,266
TradjentaLinagliptin31$26,669
RestasisCyclosporine36$22,698
LinzessLinaclotide38$21,639
RybelsusSemaglutide14$16,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$335$157,570195 claims
AbbVieCreon, Restasis, Linzess$599$97,479114 claims
MerckJanuvia, Janumet$39$92,25189 claims
AstraZenecaFarxiga, Brilinta$1,401$79,83290 claims
AmgenProlia$1,397$43,94027 claims
PfizerEliquis$14$42,85852 claims
Lilly USA, LLCTrulicity$613$39,66031 claims
Aimmune Therapeutics, Inc.Zenpep$176$37,95528 claims
GSKTrelegy Ellipta, Shingrix, Incruse Ellipta$730$29,87596 claims
GileadVemlidy$371$29,78417 claims
Novo NordiskRybelsus$1,123$16,58814 claims
Johnson & JohnsonXarelto$318$11,15912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.

Other medical in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →